PR (Progesterone Receptor)
5 drugsPredictive biomarker for patient selection in 9 indications
5
Approved Drugs
9
Indications
5
Companies
PR (Progesterone Receptor) is a precision-medicine biomarker linked to 5 FDA-approved targeted drugs from 5 companies, spanning 9 indications including Heavy Menstrual Bleeding, Uterine Leiomyoma, Endometriosis. Explore the targeted therapies, indications, testing methods, and companies developing PR (Progesterone Receptor) drugs below.
Search PR (Progesterone Receptor) Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PR (Progesterone Receptor)
| Drug | Company | Therapeutic Area |
|---|---|---|
| KORLYM | CORCEPT THERAP | Metabolic |
| MIFEPREX | DANCO LABS LLC | Metabolic |
| MIFEPRISTONE | EVITA SOLUTIONS | Metabolic |
| MYFEMBREE | SUMITOMO PHARMA AM | Women's Health |
| NUBEQA | Bayer | Oncology |
PR (Progesterone Receptor) Indications
Heavy Menstrual Bleeding Uterine Leiomyoma Endometriosis Hyperglycemia Hypercortisolism Cushing's Syndrome Type 2 Diabetes Glucose Intolerance Prostate Cancer